Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Formulation, Characterization, and Pharmacokinetic Evaluation of Novel Glipizide-phospholipid Nano-complexes with Improved Solubility and Bio-availability

Author(s): Sandeep Rathor* and Dinesh Chandra Bhatt

Volume 10, Issue 2, 2022

Published on: 16 May, 2022

Page: [125 - 136] Pages: 12

DOI: 10.2174/2211738510666220328151512

Price: $65

Abstract

Background: The proposed study was aimed to formulate and evaluate the glipizidephospholipid nano-complex. Since glipizide is a poorly soluble drug, its complexation with phospholipids is an ideal approach to improving solubility.

Methods: To improve the oral potency of glipizide, its phospholipid complex was prepared by employing the solvent evaporation method. The formulations were characterized using DSC, FTIR, PXRD, SEM, TEM, and hot stage microscopy (HSM). Solubility tests of the glipizidephospholipid nano-complex revealed a significant increase in aqueous solubility compared to glipizide's physical combination. The oral bioavailability of the glipizide-phospholipid nanocomplex was measured by using HPLC in Wistar rats’ plasma. FTIR and PXRD results revealed no significant interaction between the drug and the phospholipid in the formulation. SEM and TEM studies confirmed the morphology of the formulation assuring the conversion of crystalline form into an amorphous structure.

Results: The glipizide-phospholipid nano-complex had a greater peak plasma concentration (5.2 vs. 3.8 g/mL), a larger AUC (26.31 vs. 19.55 μgh/L), and a longer T1/2 (2.1 vs. 4.1 h) than free glipizide, indicating that it improved drug dissolution rate.

Conclusion: The outcomes suggested that a phospholipid complexation is a potential approach to increasing water-insoluble drugs' oral bioavailability.

Keywords: Glipizide, glipizide-phospholipid complex, pharmacokinetic, oral bioavailability, diabetes mellitus, hyperglycemia.

« Previous Next »
Graphical Abstract

[1]
Arunachalam S, Gunasekaran S. Diabetic research in India and China today: From literature-based mapping to health-care policy. Curr Sci 2002; 9(10): 1086-97.
[2]
Nolte MS, Karam JH. Pancreatic hormones and antidiabetic drugsBasic and clinical pharmacology. New York: Lange Medical Books/McGraw-Hill Publishing Division 2001; pp. 711-34.
[3]
Guariguata L, Whiting D, Weil C, Unwin N. The international diabetes federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. Diabetes Res Clin Pract 2011; 94(3): 322-32.
[http://dx.doi.org/10.1016/j.diabres.2011.10.040] [PMID: 22100977]
[4]
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N. Global and regional diabetes prevalence estimates for 2019 and pro-jections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. 9th ed. Diabetes Research and Clinical Practice 2019; p. 107843.
[5]
Tommansini R. Pharmacological activity of glipizide. Curr Med Res Opin 1975; 3: 7-19.
[http://dx.doi.org/10.1185/03007997509111970]
[6]
Palmer KJ, Brogden RN. Gliclazide an update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993; 46(1): 92-125.
[http://dx.doi.org/10.2165/00003495-199346010-00007] [PMID: 7691511]
[7]
Rorsman P, Ashcroft FM. Pancreatic β-cell electrical activity and insulin secretion: of mice and men. Physiol Rev 2018; 98(1): 117-214.
[http://dx.doi.org/10.1152/physrev.00008.2017] [PMID: 29212789]
[8]
Thulé PM, Umpierrez G. Sulfonylureas: A new look at old therapy. Curr Diab Rep 2014; 14(4): 473.
[http://dx.doi.org/10.1007/s11892-014-0473-5] [PMID: 24563333]
[9]
Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci 2015; 11(4): 840-8.
[http://dx.doi.org/10.5114/aoms.2015.53304] [PMID: 26322096]
[10]
Erickson ML, Little JP, Gay JL, McCully KK, Jenkins NT. Effects of postmeal exercise on postprandial glucose excursions in people with type 2 diabetes treated with add-on hypoglycemic agents. Diabetes Res Clin Pract 2017; 126(126): 240-7.
[http://dx.doi.org/10.1016/j.diabres.2017.02.015] [PMID: 28284168]
[11]
Cullis PR, de Kruijff B. Lipid polymorphism and the functional roles of lipids in biological membranes. Biochim Biophys Acta 1979; 559(4): 399-420. [BBA
[http://dx.doi.org/10.1016/0304-4157(79)90012-1] [PMID: 391283]
[12]
Yang R, Zhang X, Li F. Role of phospholipids and copolymers in enhancing stability and controlling degradation of intravenous lipid emulsion. Colloidal and surface A. Physicochem Eng 2013; 436: 434-42.
[http://dx.doi.org/10.1016/j.colsurfa.2013.07.022]
[13]
Haynes DH. Phospholipid-coated microcrystals: Injectable formulations of water-insoluble drugs. Google Patents 1992.
[14]
Tunçdemir M, Ertürküner SP, Özçelik D. Investigation of lipid peroxidation and antiapoptotic effects of zinc aganist liver damage in dia-betic rats. Hum Exp Toxicol 2017; 36(8): 813-22.
[http://dx.doi.org/10.1177/0960327116666619] [PMID: 27609014]
[15]
Cai X, Luan Y, Jiang Y, et al. Huperzine A-phospholipid complex-loaded biodegradable thermosensitive polymer gel for controlled drug release. Int J Pharm 2012; 433(1-2): 102-11.
[http://dx.doi.org/10.1016/j.ijpharm.2012.05.009] [PMID: 22583846]
[16]
Drescher S, van Hoogevest P. The phospholipid research center: Current research in phospholipids and their use in drug delivery. Pharmaceutics 2020; 12(12): 1235.
[http://dx.doi.org/10.3390/pharmaceutics12121235] [PMID: 33353254]
[17]
Maiti K, Mukherjee K, Gangtait A. Enhanced therapeutic benefit of quercetin phospholipid complex in carbon tetrachloride-induced acute liver injury in rats: A comparative study. Iranian J Pharmacol Ther 2005; 4: 84-90.
[18]
Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Enhanced therapeutic potential of naringenin-phospholipid complex in rats. J Pharm Pharmacol 2006; 58(9): 1227-33.
[http://dx.doi.org/10.1211/jpp.58.9.0009] [PMID: 16945181]
[19]
Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007; 330(1-2): 155-63.
[http://dx.doi.org/10.1016/j.ijpharm.2006.09.025] [PMID: 17112692]
[20]
Rezhdo O, Speciner L, Carrier R. Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement. J Control Release 2016; 240: 544-60.
[http://dx.doi.org/10.1016/j.jconrel.2016.07.050] [PMID: 27520734]
[21]
Patil JS, Suresh S, Sureshbabu AR, Rajesh MS. Development and validation of liquid chromatography-mass spectrometry method for the estimation of rifampicin in plasma. Indian J Pharm Sci 2011; 73(5): 558-63.
[http://dx.doi.org/10.4103/0250-474X.99014] [PMID: 22923869]
[22]
Schreier S, Malheiros SVP, de Paula E. Surface active drugs: Self-association and interaction with membranes and surfactants. Physico-chemical and biological aspects. Biochim Biophys Acta 2000; 1508(1-2): 210-34.
[http://dx.doi.org/10.1016/S0304-4157(00)00012-5] [PMID: 11090827]
[23]
Semalty A, Semalty M, Singh D, Rawat MSM. Development and characterization of aspirin-phospholipid complex for improved drug delivery. Int JPharm Sci Nanotechnol 2010; 3: 940-7.
[http://dx.doi.org/10.37285/ijpsn.2010.3.2.7]
[24]
Khomane K, Kumar L, Meena CL, Jain R, Bansal A. NP-647, a novel TRH analogue: Investigating physicochemical parameters critical for its oral and parenteral delivery. Int J Pharm 2011; 406(1-2): 21-30.
[http://dx.doi.org/10.1016/j.ijpharm.2010.12.025] [PMID: 21185925]

Rights & Permissions Print Cite
Article Metrics
31
1
© 2024 Bentham Science Publishers | Privacy Policy